Skip to main content

Table 2 Patient’s characteristics according to radiation dose to internal mammary lymph node

From: Optimal radiotherapy for patients with internal mammary lymph node metastasis from breast cancer

CharacteristicsNumber of patients (%)p-value
50–63.5 Gy 1)(n = 35)63.6–70.4 Gy 1)(n = 49)
Age≤ 40 years15 (42.9%)23 (46.9%)0.825
>  40 years20 (57.1%)26 (53.1%)
Histologic grade1–223 (71.9%)22 (51.2%)0.096
39 (28.1%)21 (48.8%)
SubtypesNon-TNBC22 (62.9%)32 (65.3%)0.822
TNBC13 (37.1%)17 (34.7%)
cT stages1–219 (54.3%)28 (57.1%)0.827
3–416 (45.7%)21 (42.9%)
cN stages2b or 3b26 (74.3%)37 (75.5%)1.000
3c9 (25.7%)12 (24.5%)
FNABx for IMN(−) or unknown20 (57.1%)24 (49.0%)0.511
(+)15 (42.9%)25 (51.0%)
Extent of the IMNSingle ICS13 (37.1%)24 (49.0%)0.373
Multiple ICS22 (62.9%)25 (51.0%)
IMN long diameter<  1.0 cm20 (57.1%)22 (44.9%)0.376
≥ 1.0 cm15 (42.9%)27 (55.1%)
Neoadjuvant chemotherapyNot done9 (25.7%)9 (18.4%)0.433
Done26 (74.3%)40 (81.6%)
Primary surgeryBCS22 (62.9%)18 (36.7%)0.026
Mastectomy13 (37.1%)31 (63.3%)
Axillary surgeryALND30 (85.7%)44 (89.8%)0.735
SLNB5 (14.3%)5 (10.2%)
  1. 1)Radiotherapy dose was calculated using the biologically equivalent dose in 2 Gy fractions (EQD2) assuming the α/β ratio of 3.5 Gy
  2. Abbreviations: TNBC Triple-negative breast cancer, IMN Internal mammary node, FNABx Fine needle aspiration biopsy, ICS Intercostal space, BCS Breast conserving surgery, ALND Axillary lymph node dissection, SLNB Sentinel lymph node biopsy